Desmoglein-2 as a prognostic and biomarker in ovarian cancer

References

• Key Statistics for Ovarian Cancer. Available from URL: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html
   Google Scholar
• Curti BD. Physical barriers to drug delivery in tumors. Crit Rev Oncol Hematol. 1993;14:29–39. doi:10.1016/1040-8428(93)90004-N.
   PubMed Web of Science ®Google Scholar
• Anderson JM. Molecular structure of tight junctions and their role in epithelial transport. Physiology. 2001;16:126–130. doi:10.1152/physiologyonline.2001.16.3.126.
   Google Scholar
• Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol. 2009;1:a002584. doi:10.1101/cshperspect.a002584.
   PubMed Web of Science ®Google Scholar
• Guttman JA, Finlay BB. Tight junctions as targets of infectious agents. Biochimica Et Biophysica Acta (Bba)-biomembranes. 2009;1788:832–841. doi:10.1016/j.bbamem.2008.10.028.
   PubMed Web of Science ®Google Scholar
• Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–1323. doi:10.1126/science.275.5304.1320.
   PubMed Web of Science ®Google Scholar
• Wang H, Li ZY, Liu Y, Persson J, Beyer I, Moller T, Koyuncu D, Drescher MR, Strauss R, Zhang XB, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17:96–104. doi:10.1038/nm.2270.
   PubMed Web of Science ®Google Scholar
• Garrod D, Chidgey M. Desmosome structure, composition and function. Biochimica Et Biophysica Acta (Bba)-biomembranes. 2008;1778:572–587. doi:10.1016/j.bbamem.2007.07.014.
   PubMed Web of Science ®Google Scholar
• Klessner JL, Desai BV, Amargo EV, Getsios S, Green KJ, Nusrat A. EGFR and ADAMs cooperate to regulate shedding and endocytic trafficking of the desmosomal cadherin desmoglein 2. Mol Biol Cell. 2009;20:328–337. doi:10.1091/mbc.e08-04-0356.
   PubMed Web of Science ®Google Scholar
• Wang H, Ducournau C, Saydaminova K, Richter M, Yumul R, Ho M, Carter D, Zubieta C, Fender P, Lieber A. Intracellular signaling and desmoglein 2 shedding triggered by human adenoviruses Ad3, Ad14, and Ad14P1. J Virol. 2015;89:10841–10859. doi:10.1128/JVI.01425-15.
   PubMed Web of Science ®Google Scholar
• Brennan D, Mahoney MG. Increased expression of Dsg2 in malignant skin carcinomas: A tissue-microarray based study. Cell Adh Migr. 2009;3:148–154. doi:10.4161/cam.3.2.7539.
   PubMed Web of Science ®Google Scholar
• Harada H, Iwatsuki K, Ohtsuka M, Han GW, Kaneko F. Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm Venereol. 1996;76:417–420.
   PubMed Web of Science ®Google Scholar
• Cai F, Zhu Q, Miao Y, Shen S, Su X, Shi Y. Desmoglein-2 is overexpressed in non-small cell lung cancer tissues and its knockdown suppresses NSCLC growth by regulation of p27 and CDK2. J Cancer Res Clin Oncol. 2017;143:59–69. doi:10.1007/s00432-016-2250-0.
   PubMed Web of Science ®Google Scholar
• Sun R, Ma C, Wang W, Yang S. Upregulation of desmoglein 2 and its clinical value in lung adenocarcinoma: a comprehensive analysis by multiple bioinformatics methods. PeerJ. 2020;8:e8420. doi:10.7717/peerj.8420.
   PubMed Web of Science ®Google Scholar
• Jin R, Wang X, Zang R, Liu C, Zheng S, Li H, Sun N, He J. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. Cancer Lett. 2020;483:46–58. doi:10.1016/j.canlet.2020.04.001.
   PubMed Web of Science ®Google Scholar
• Han CP, Yu YH, Wang AG, Tian Y, Zhang HT, Zheng ZM, Liu YS. Desmoglein-2 overexpression predicts poor prognosis in hepatocellular carcinoma patients. Eur Rev Med Pharmacol Sci. 2018;22:5481–5489.
   PubMed Web of Science ®Google Scholar
• Biedermann K, Vogelsang H, Becker I, Plaschke S, Siewert JR, Hofler H, Keller G. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol. 2005;207:199–206. doi:10.1002/path.1821.
   PubMed Web of Science ®Google Scholar
• Grantab R, Sivananthan S, Tannock IF. The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res. 2006;66:1033–1039. doi:10.1158/0008-5472.CAN-05-3077.
   PubMed Web of Science ®Google Scholar
• Strauss R, Sova P, Liu Y, Li Z-Y, Tuve S, Pritchard D, Brinkkoetter P, Moller T, Wildner O, Pesonen S, et al. Epithelial phenotype of ovarian cancer mediates resistance to oncolytic adenoviruses. Cancer Res. 2009;15:5115–5125. doi:10.1158/0008-5472.CAN-09-0645.
   Google Scholar
• Beyer I, Cao H, Persson J, Song H, Richter M, Feng Q, Yumul R, van Rensburg R, Li Z, Berenson R, et al. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin Cancer Res. 2012;18:3340–3351. doi:10.1158/1078-0432.CCR-11-3213.
   PubMed Web of Science ®Google Scholar
• Beyer I, van Rensburg R, Lieber A. Overcoming physical barriers in cancer therapy. Tissue Barriers. 2013;1:e23647. doi:10.4161/tisb.23647.
   PubMedGoogle Scholar
• Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, Song H, Bartek J, et al. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res. 2011;71:7080–7090. doi:10.1158/0008-5472.CAN-11-2009.
   PubMed Web of Science ®Google Scholar
• Wang CE, Yumul RC, Lin J, Cheng Y, Lieber A, Pun SH. Junction opener protein increases nanoparticle accumulation in solid tumors. J Control Release. 2018;272:9–16. doi:10.1016/j.jconrel.2017.12.032.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Z, Yumul R, Lara S, Hemminki A, Fender P, Lieber A. Multimerization of adenovirus serotype 3 fiber knob domains is required for efficient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol. 2011;85:6390–6402. doi:10.1128/JVI.00514-11.
   PubMed Web of Science ®Google Scholar
• Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics. 2009;8:661–669. doi:10.1074/mcp.M800313-MCP200.
   PubMed Web of Science ®Google Scholar
• Xie H, Xu H, Hou Y, Cai Y, Rong Z, Song W, Wang W, Li K. Integrative prognostic subtype discovery in high-grade serous ovarian cancer. J Cell Biochem. 2019;120:18659–18666. doi:10.1002/jcb.29049.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu X, Zhang J, Liu Y, Gao A, Xu Y, Lin Y, Du Q, Zhu Z, Hu Y, et al. Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma. Int J Clin Exp Pathol. 2018;11:4977–4986.
   PubMed Web of Science ®Google Scholar
• Richter M, Yumul R, Wang H, Saydaminova K, Ho M, May D, Baldessari A, Gough M, Drescher C, Urban N, et al. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin. Mol Ther Methods Clin Dev. 2015;2:15005. doi:10.1038/mtm.2015.5.
   PubMed Web of Science ®Google Scholar
• Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol. 2013;130:518–524. doi:10.1016/j.ygyno.2013.06.003.
   PubMed Web of Science ®Google Scholar
• Hemminki O, Bauerschmitz G, Hemmi S, Kanerva A, Cerullo V, Pesonen S, Hemminki A. Preclinical and clinical data with a fully serotype 3 oncolytic adenovirus Ad3-hTERT-E1A in the treatment of advanced solid tumors.. Molecular Therapy. 2010;18:S74.
   Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874–1884. doi:10.1038/mt.2010.161.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Møller ASW. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein‐2 cell entry receptor. J Med Virol. 2020;92(9):1309–1315.
   PubMed Web of Science ®Google Scholar
• Saydaminova K, Strauss R, Xie M, Bartek J, Richter M, van Rensburg R, Drescher C, Ehrhardt A, Ding S, Lieber A. Sensitizing ovarian cancer cells to chemotherapy by interfering with pathways that are involved in the formation of cancer stem cells. Cancer Biol Ther. 2016;17:1079–1088. doi:10.1080/15384047.2016.1219819.
   PubMed Web of Science ®Google Scholar
• Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS One. 2011;6:e16186. doi:10.1371/journal.pone.0016186.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, Du Bois A, Kristensen G, Jakobsen A, Sagae S, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the gynecological cancer intergroup (GCIG). Int J Gynecol Cancer. 2011;21:419–423. doi:10.1097/IGC.0b013e3182070f17.
   PubMed Web of Science ®Google Scholar
• Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellstrom I, Hellstrom KE, Urban N. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125:65–69. doi:10.1016/j.ygyno.2011.11.050.
   PubMed Web of Science ®Google Scholar
• Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res. 2002;8:878–884.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–592. doi:10.1038/nrc1893.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2003;21:3194–3200. doi:10.1200/JCO.2003.02.153.
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–2529. doi:10.1056/NEJMra041842.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a north Thames ovary group study. Ann Oncol. 1996;7:361–364. doi:10.1093/oxfordjournals.annonc.a010602.
   PubMed Web of Science ®Google Scholar
• Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–1163. doi:10.1016/S0140-6736(10)61268-8.
   PubMed Web of Science ®Google Scholar
• Peitsch WK, Doerflinger Y, Fischer-Colbrie R, Huck V, Bauer AT, Utikal J, Goerdt S, Schneider SW. Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells. PLoS One. 2014;9:e89491. doi:10.1371/journal.pone.0089491.
   PubMed Web of Science ®Google Scholar
• Kamekura R, Kolegraff KN, Nava P, Hilgarth RS, Feng M, Parkos CA, Nusrat A. Loss of the desmosomal cadherin desmoglein-2 suppresses colon cancer cell proliferation through EGFR signaling. Oncogene. 2014;33:4531–4536. doi:10.1038/onc.2013.442.
   PubMed Web of Science ®Google Scholar
• Barber AG, Castillo-Martin M, Bonal DM, Rybicki BA, Christiano AM, Cordon-Cardo C, Robson CN. Characterization of desmoglein expression in the normal prostatic gland. Desmoglein 2 is an independent prognostic factor for aggressive prostate cancer. PLoS One. 2014;9:e98786. doi:10.1371/journal.pone.0098786.
   PubMed Web of Science ®Google Scholar
• Yashiro M, Nishioka N, Hirakawa K. Decreased expression of the adhesion molecule desmoglein-2 is associated with diffuse-type gastric carcinoma. Eur J Cancer. 2006;42:2397–2403. doi:10.1016/j.ejca.2006.03.024.
   PubMed Web of Science ®Google Scholar
• Hutz K, Zeiler J, Sachs L, Ormanns S, Spindler V. Loss of desmoglein 2 promotes tumorigenic behavior in pancreatic cancer cells. Mol Carcinog. 2017;56:1884–1895. doi:10.1002/mc.22644.
   PubMed Web of Science ®Google Scholar
• Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006;66:8319–8326. doi:10.1158/0008-5472.CAN-06-0410.
   PubMed Web of Science ®Google Scholar
• Wang H, Beyer I, Persson J, Song H, Li Z, Richter M, Cao H, van Rensburg R, Yao X, Hudkins K, et al. A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenoviruses. J Virol. 2012;86:6286–6302.
   PubMed Web of Science ®Google Scholar
• Seiden MV. Progress in gynecologic cancer. Semin Oncol. 2009;36:90. doi:10.1053/j.seminoncol.2008.12.010.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW. Chimeric oncolytic Ad5/3 virus replicates and lyses ovarian cancer cells through desmoglein-2 cell entry receptor. J Med Virol. 2020;92:1309–1315. doi:10.1002/jmv.25677.
   PubMed Web of Science ®Google Scholar
• Ormanns S, Altendorf-Hofmann A, Jackstadt R, Horst D, Assmann G, Zhao Y, Bruns C, Kirchner T, Knosel T. Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Br J Cancer. 2015;113:1460–1466. doi:10.1038/bjc.2015.362.
   PubMed Web of Science ®Google Scholar
• Yumul R, Richter M, Lu ZZ, Saydaminova K, Wang H, Wang CH, Carter D, Lieber A. Epithelial junction opener improves oncolytic adenovirus therapy in mouse tumor models. Hum Gene Ther. 2016;27:325–337. doi:10.1089/hum.2016.022.
   PubMed Web of Science ®Google Scholar
• Chou J, Fitzgibbon MP, Mortales CL, Towlerton AM, Upton MP, Yeung RS, McIntosh MW, Warren EH, Cheung ST. Phenotypic and transcriptional fidelity of patient-derived colon cancer xenografts in immune-deficient mice. PLoS One. 2013;8:e79874. doi:10.1371/journal.pone.0079874.
   PubMed Web of Science ®Google Scholar